<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631550</url>
  </required_header>
  <id_info>
    <org_study_id>SP-302 RIME</org_study_id>
    <nct_id>NCT03631550</nct_id>
  </id_info>
  <brief_title>The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine</brief_title>
  <official_title>The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurolief Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurolief Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study will evaluate the clinical performance and safety of a self administered abortive&#xD;
      treatment for migraine headache using combined occipital and supraorbital transcutaneous&#xD;
      nerve stimulator (Neurolief device, Relivion TM)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Actual">August 4, 2020</completion_date>
  <primary_completion_date type="Actual">August 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects reporting reduction of migraine headache pain at 2 hours from treatment initiation</measure>
    <time_frame>2 hours from treatment initiation</time_frame>
    <description>Proportion of subjects reporting reduction of migraine headache pain 2 hours post treatment initiation from severe or moderate to mild or no pain, or from mild to no pain, in their first eligible treated migraine attack (if rescue therapy was not used)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reporting improvement in their Most Bothersome Symptom (MBS) other than a headache, 2 hours post-treatment initiation</measure>
    <time_frame>2 hours from treatment initiation</time_frame>
    <description>Proportion of subjects reporting improvement in their Most Bothersome Symptom (MBS) other than a headache, 2 hours post-treatment initiation (if rescue therapy was not used), in their first eligible treated migraine attack. MBS may be nausea, photophobia, phonophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reporting reduction of migraine headache pain 1-hour post treatment initiation</measure>
    <time_frame>1 hour from treatment initiation</time_frame>
    <description>Proportion of subjects reporting reduction of migraine headache pain 1-hour post treatment initiation (if rescue therapy was not used), from severe or moderate to mild or no pain, or from mild to no pain, in their first eligible treated migraine attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are pain free at 2 hours post treatment initiation</measure>
    <time_frame>2 hours from treatment initiation</time_frame>
    <description>Proportion of subjects who are pain free at 2 hours post treatment initiation (if rescue therapy was not used), in their first eligible treated migraine attack</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Endpoint[Rate of Adverse events related or unrelated to the study device]</measure>
    <time_frame>24 hours post treatment initiation</time_frame>
    <description>Safety of the study device following study treatment: Rate of Adverse events related or unrelated to the study device</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Relivion Active device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Relivion Sham device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Relivion active</intervention_name>
    <description>1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Relivion Sham</intervention_name>
    <description>1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects 18 years of age and older.&#xD;
&#xD;
          2. Subject meets the ICHD (International Classification of Headache Disorders)-3 (2018)&#xD;
             diagnostic criteria for Migraine with or without aura.&#xD;
&#xD;
          3. Subject reports 1-6 Migraine attacks per month; other headaches no more than 6 days&#xD;
             per month.&#xD;
&#xD;
          4. Subject is willing to and capable of complying with the specified study requirements,&#xD;
             provided written Informed Consent, can complete the electronic diaries, and can be&#xD;
             contacted by telephone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject having received Botox treatment in the head region in the prior 3 months.&#xD;
&#xD;
          2. Subject having received supraorbital or occipital nerve blocks in the prior month.&#xD;
&#xD;
          3. Past 6 months of chronic migraine, New Daily Persistent Headache, and chronic&#xD;
             tension-type headache per ICHD-3 (2018) diagnostic criteria.&#xD;
&#xD;
          4. Current medication overuse headache.&#xD;
&#xD;
          5. Use of opioid medications in the prior 1 month.&#xD;
&#xD;
          6. Use of barbiturates in the prior 1 month.&#xD;
&#xD;
          7. Subject has &gt;10 headache days per month&#xD;
&#xD;
          8. Implanted metal/shrapnel or electrical devices in the head (not including dental&#xD;
             implants), a cardiac pacemaker or an implanted or wearable defibrillator.&#xD;
&#xD;
          9. Received parenteral infusions for migraine within the previous 2 weeks.&#xD;
&#xD;
         10. Subject has known uncontrolled epilepsy.&#xD;
&#xD;
         11. History of neurosurgical interventions&#xD;
&#xD;
         12. Subject with implanted neurostimulators, surgical clips (above the shoulder line) or&#xD;
             any medical pumps.&#xD;
&#xD;
         13. Current drug abuse or alcoholism.&#xD;
&#xD;
         14. Subject is participating in any other clinical study.&#xD;
&#xD;
         15. Skin lesion or inflammation at the region of the stimulating electrodes.&#xD;
&#xD;
         16. Personality or somatoform disorder.&#xD;
&#xD;
         17. Pregnancy or Lactation.&#xD;
&#xD;
         18. Women with child bearing potential without medically acceptable method of&#xD;
             contraception (NOTE: Females of child bearing potential must have a negative pregnancy&#xD;
             test).&#xD;
&#xD;
         19. Documented history of cerebrovascular event.&#xD;
&#xD;
         20. Subject with recent brain or facial trauma (occurred less than 3 months prior to this&#xD;
             study).&#xD;
&#xD;
         21. Subject participated in a previous study with the Relivion device.&#xD;
&#xD;
         22. The subject does not have the basic cognitive and motor skills needed to operate a&#xD;
             smartphone.&#xD;
&#xD;
         23. Subject with head circumference smaller than 51 centimeters or head circumference&#xD;
             larger than 60 centimeters&#xD;
&#xD;
         24. Subject with other significant pain problem that in the opinion of the investigator&#xD;
             may confound the study assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stewart J. Tepper, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Consortium, an AMR company</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford HealthCare Headache Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium, an AMR company</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai MC</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharei Zedek MC</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macabi healtcenter services</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laniado MC</name>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macabi healtcenter services</name>
      <address>
        <city>Ra'anana</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

